Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 609
Filtrar
2.
Pediatr Allergy Immunol ; 35(5): e14130, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38693814

RESUMEN

While the early introduction of food allergens in the infant diet has been shown to be effective at preventing the development of food allergy (FA), its implementation in real life has been associated with various challenges. Interventions aimed at correcting skin barrier dysfunction have been explored in recent decades as a distinct or complementary mean to prevent allergic sensitization through the skin and subsequent development of FA. Studies assessing the application of emollient from birth have yielded conflicting results, and meta-analyses have demonstrated either no effect or only a slight positive effect on FA prevention. However, a careful review of the clinical trials reveals that different emollients were used, which may have explained some of the discrepancies between study results. Emollient application protocols also varied widely between studies. While firm conclusions cannot be drawn with regard to their overall efficacy at preventing FA, the available data provide valuable insight into the characteristics that could be associated with a more effective intervention. Namely, successful trials tended to use emollients with an acidic pH of 5.5, applied over the entire body, and combined with topical corticosteroids in affected areas. Consensus on the optimal strategy to restore skin barrier function could help improve the homogeneity and clinical relevance of future trials on this topic. In the meantime, clinicians should avoid products associated with worse outcomes.


Asunto(s)
Emolientes , Hipersensibilidad a los Alimentos , Piel , Humanos , Hipersensibilidad a los Alimentos/prevención & control , Emolientes/administración & dosificación , Piel/efectos de los fármacos , Piel/inmunología , Lactante , Alérgenos/inmunología , Alérgenos/administración & dosificación , Ensayos Clínicos como Asunto , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Recién Nacido
3.
PLoS One ; 19(5): e0302969, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38743769

RESUMEN

BACKGROUND: Synthesizing current evidence on interventions to improve survival outcomes in preterm infants is crucial for informing programs and policies. The objective of this study is to investigate the impact of topical emollient oil application on the weight of preterm infants. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. To identify relevant studies, comprehensive searches were conducted across multiple databases, including PubMed, Cochrane, Scopus, Clinical trials, ProQuest Central, Epistemonikos, and gray literature sources. The inclusion criteria were based on the PICO (Population, Intervention, Comparison, and Outcomes) format. Study quality was assessed using the Cochrane risk of bias tool for randomized trials (RoB 2.0). Data analysis was performed using StataCrop MP V.17 software, which included evaluating heterogeneity, conducting subgroup analysis, sensitivity analysis, and meta-regression. The findings were reported in accordance with the PRISMA checklist, and the review was registered with PROSPERO (CRD42023413770). RESULTS: Out of the initial pool of 2734 articles, a total of 18 studies involving 1454 preterm neonates were included in the final analysis. Fourteen of these studies provided data that contributed to the calculation of the pooled difference in mean weight gain in preterm neonates. The random effects meta-analysis revealed a significant pooled difference in mean weight gain of 52.15 grams (95% CI: 45.96, 58.35), albeit with high heterogeneity (I2 > 93.24%, p 0.000). Subgroup analyses were conducted, revealing that preterm infants who received massages three times daily with either sunflower oil or coconut oil exhibited greater mean differences in weight gain. Meta-regression analysis indicated that the type of emollient oil, duration of therapy, and frequency of application significantly contributed to the observed heterogeneity. A sensitivity analysis was performed, excluding two outlier studies, resulting in a pooled mean weight difference of 78.57grams (95% CI: 52.46, 104.68). Among the nine studies that reported adverse events, only two mentioned occurrences of rash and accidental slippage in the intervention groups. CONCLUSION: The available evidence suggests that the application of topical emollient oil in preterm neonates is likely to be effective in promoting weight gain, with a moderate-to-high level of certainty. Based on these findings, it is recommended that local policymakers and health planners prioritize the routine use of emollient oils in newborn care for preterm infants. By incorporating emollient oils into standard care protocols, healthcare providers can provide additional support to promote optimal growth and development in preterm infants.


Asunto(s)
Emolientes , Recien Nacido Prematuro , Humanos , Recién Nacido , Emolientes/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Administración Tópica , Aumento de Peso/efectos de los fármacos
4.
J Cosmet Dermatol ; 23(5): 1758-1765, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38299457

RESUMEN

INTRODUCTION: Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene are recommended as the first-line therapy for mild to moderate acne. However, the cutaneous irritations may occur, and the dermocosmetics are recommended to prevent side effects of anti-acne drugs and adhere to treatment. Thus, this study aims to compare the efficacy and tolerability of ceramides and niacinamide-containing moisturizer (CCM) versus hydrophilic cream in combination with topical anti-acne treatment in mild to moderate acne vulgaris. METHODS: This was an 8-week, randomized, double-blinded, split face study in 40 patients assigned for topical anti-acne medications (5% benzoyl peroxide and 0.1% adapalene gel), then randomly applied CCM or hydrophilic cream. All patients were followed at week 0, 2, 4, and 8 for acne improvement, adverse reactions, biometric, and biophysical evaluation. RESULTS: CCM could significantly improve the non-inflammatory, inflammatory, and total acne lesions compared with hydrophilic cream after week 8 of treatment. Interestingly, there was an improvement of global worst score, hemoglobin index, melanin index, TEWL, skin hydration, sebum production, and skin surface pH, with no statistically significant differences between the two treatments. No serious side effects from clinical application of CCM and hydrophilic cream in mild to moderate acne vulgaris patients. CONCLUSION: Ceramide and niacinamide-containing moisturizer in combination with anti-acne medication can significantly improve acne lesions and decrease cutaneous irritations toward a satisfactory treatment outcome of mild to moderate acne vulgaris.


Asunto(s)
Acné Vulgar , Adapaleno , Administración Cutánea , Ceramidas , Fármacos Dermatológicos , Niacinamida , Índice de Severidad de la Enfermedad , Crema para la Piel , Humanos , Acné Vulgar/tratamiento farmacológico , Método Doble Ciego , Niacinamida/administración & dosificación , Niacinamida/efectos adversos , Femenino , Masculino , Crema para la Piel/administración & dosificación , Crema para la Piel/efectos adversos , Ceramidas/administración & dosificación , Adulto Joven , Adulto , Resultado del Tratamiento , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Adapaleno/administración & dosificación , Adolescente , Peróxido de Benzoílo/administración & dosificación , Peróxido de Benzoílo/efectos adversos , Quimioterapia Combinada , Emolientes/administración & dosificación , Combinación de Medicamentos
5.
J Cosmet Dermatol ; 23(6): 2097-2102, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38400600

RESUMEN

BACKGROUND: Prolonged use of medical masks has increased skin-related issues. AIM: To evaluate the efficacy of a facial cream and facial mask in mitigating medical mask related skin symptoms. METHODS: Healthy women were randomly assigned to apply a facial cream (n = 32) or a facial mask plus a facial cream (n = 32) on half-faces after wearing medical masks for 4 h (Tb). Transepidermal water loss (TEWL), dryness score, and redness area were assessed at Tb and 10 min after using the cream (T1) in the facial cream group, and at Tb, 1 h after using the facial mask (T2), and 10 min after using the cream (T3) in the combined use group. RESULTS: In the facial cream group, the treated half-face showed significantly better improvements from Tb to T1 in TEWL (-2.95 ± 0.38 vs. -0.68 ± 0.35 g/h·cm2, p < 0.001) and skin dryness score (-1.00 ± 0.12 vs. 0.00 ± 0.00, p < 0.001). In the combined use group, the treated half-face showed significantly better improvements from Tb to T2 and T3 in TEWL (T2, -3.46 ± 0.33 vs. -0.09 ± 0.13 g/h·cm2; T3, -4.67 ± 0.31 vs. -0.28 ± 0.22 g/h·cm2) and skin dryness score (T2, -0.63 ± 0.13 vs. 0.03 ± 0.03; T3, -0.94 ± 0.17 vs. 0.19 ± 0.07) (all p < 0.001) then the untreated half-face. The combined use group had significantly lower TEWL at T3 than T2 (p < 0.05). The reduction in redness area was similar between the treated and untreated half-faces in both groups. CONCLUSIONS: The test facial cream and mask significantly improved skin barrier function and alleviated dryness symptoms associated with medical mask use, with the combined use offering superior benefits.


Asunto(s)
Máscaras , Crema para la Piel , Pérdida Insensible de Agua , Humanos , Femenino , Adulto , Crema para la Piel/administración & dosificación , Crema para la Piel/efectos adversos , Pérdida Insensible de Agua/efectos de los fármacos , Máscaras/efectos adversos , Cara , Resultado del Tratamiento , Adulto Joven , Eritema/etiología , Eritema/prevención & control , Persona de Mediana Edad , Emolientes/administración & dosificación , Voluntarios Sanos , Piel/efectos de los fármacos
6.
J Cosmet Dermatol ; 23(5): 1533-1540, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38214440

RESUMEN

BACKGROUND: Moisturizers are designed to maintain skin health and treat dermatological conditions associated with impaired skin barrier function. However, differences in their composition account for the differences in their effect. AIMS: This narrative review aims to discuss the role of barrier repair moisturizers, highlight the role of different components in a moisturizer and their role in impaired skin conditions (e.g., dry, itchy, inflamed, sensitive skin, atopic eczema), and thereby empower dermatologists and pediatricians in selecting the right moisturizer. METHODS: PubMed, Embase, and Scopus electronic databases were searched from January 2000 to June 2023 for publications on skin barrier repair and use of barrier repair moisturizers for the treatment of dry, itchy, inflamed, sensitive skin, or atopic eczema. Studies conducted in humans, published in English for which full texts were freely available were included. RESULTS: The structure and composition of lipid lamellae within the stratum corneum play an important role in maintaining an effective skin barrier and protecting the body from various external assaults. Endocannabinoid mediators play an active role in maintaining skin barrier function. Moisturizers containing physiological lipids and functional ingredients (e.g., endocannabinoids such as palmitoylethanolamide [PEA]) and based on the principles of biomimic technology are demonstrated to be beneficial for the management of conditions associated with a disrupted skin barrier. CONCLUSIONS: Moisturizer based on the innovative biomimic formulation has good cosmetic efficacy and is generally well tolerated, and the addition of PEA might represent a new generation of compounds that may be beneficial for long-term management of impaired skin conditions.


Asunto(s)
Crema para la Piel , Humanos , Crema para la Piel/administración & dosificación , Emolientes/administración & dosificación , Enfermedades de la Piel/tratamiento farmacológico , Piel/efectos de los fármacos , Piel/metabolismo , Fenómenos Fisiológicos de la Piel/efectos de los fármacos
7.
Clin Exp Dermatol ; 49(6): 573-577, 2024 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-38113393

RESUMEN

BACKGROUND: The main determinant of emollient effectiveness is whether it is used, which in turn is linked with user satisfaction. OBJECTIVES: To compare parental satisfaction with emollient type for the treatment of childhood eczema. METHODS: Secondary analysis of data from the Best Emollients for Eczema (BEE) trial was undertaken. In total, 550 children aged between 6 months and 12 years were recruited from primary care in England and randomized to use a lotion, cream, gel or ointment as their main emollient for 16 weeks. At week, 16 parents were asked to complete an Emollient Satisfaction Questionnaire (ESQ). Completion rates and scores were compared, using χ2 test, t-test calculations and one-way Anova as appropriate. RESULTS: Data on 378 participants (68.7% of those randomized) were analysed. Mean ESQ scores were gel 20.9 (SD 5.3), lotion 20.4 (SD 5.6), cream 18.8 (SD 6.3) and ointment 15.2 (SD 6.8) (P < 0.001). In pairwise comparisons, there was a statistically significant difference in mean ESQ scores between ointment and lotion (P < 0.001), ointment and cream (P < 0.001) and ointment and gel (P < 0.001) but not between lotion, cream and gel. Participants using lotions had highest overall satisfaction and were most likely to continue using their emollient. ESQ scores were correlated with reported emollient use and improvements in parent-reported eczema severity. CONCLUSIONS: Overall, lotions and gels were favoured over creams and ointments. Although satisfaction is determined by personal preference, these results will aid parents, clinicians and children to find the right emollient(s) for them.


Asunto(s)
Eccema , Emolientes , Pomadas , Padres , Humanos , Emolientes/administración & dosificación , Emolientes/uso terapéutico , Niño , Padres/psicología , Eccema/tratamiento farmacológico , Femenino , Masculino , Preescolar , Lactante , Geles , Crema para la Piel/administración & dosificación , Encuestas y Cuestionarios , Satisfacción del Paciente
8.
J Dermatolog Treat ; 34(1): 2241587, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37592879

RESUMEN

BACKGROUND: The efficacy and safety of an over-the-counter (OTC) 1% colloidal oatmeal cream versus a ceramide-based prescription barrier cream in children with mild-to-moderate atopic dermatitis (AD) were previously described. OBJECTIVES: Here, findings are reported for the Black/African American subgroup. METHODS: Patients were randomized to 1% oatmeal cream or prescription barrier cream twice daily or as needed for three weeks. Assessments included Eczema Area and Severity Index (EASI) scores, Investigator's Global Atopic Dermatitis Assessment (IGADA) scores, and patients'/caregivers' assessment of eczema signs and symptoms. RESULTS: Overall, 49 Black/African American children aged 2-15 years with mild/moderate AD were included. At week 3, mean (SD) changes from baseline in EASI scores were -2.4 (1.7) with 1% oatmeal cream and -2.1 (2.3) with barrier cream; improvements were observed from week 1. At week 3, mean (SD) changes from baseline in IGADA scores were -0.6 (0.7) and -0.7 (0.6), respectively. Improvements in subjective ratings of signs/symptoms of eczema were observed. Both study treatments were well tolerated. CONCLUSION: OTC 1% oatmeal cream was at least as effective and safe as prescription barrier cream in this population, providing a novel, fast-acting, and cost-effective option for the symptomatic treatment of mild-to-moderate AD in Black/African American children.


Asunto(s)
Avena , Dermatitis Atópica , Niño , Humanos , Negro o Afroamericano , Población Negra , Ceramidas/administración & dosificación , Ceramidas/uso terapéutico , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/etnología , Eccema/diagnóstico , Eccema/tratamiento farmacológico , Eccema/etnología , Emolientes/administración & dosificación , Emolientes/uso terapéutico , Preescolar , Adolescente , Crema para la Piel/administración & dosificación , Crema para la Piel/uso terapéutico , Administración Cutánea
9.
Am Fam Physician ; 105(1): 55-64, 2022 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-35029946

RESUMEN

Pruritus is the sensation of itching; it can be caused by dermatologic and systemic conditions. An exposure history may reveal symptom triggers. A thorough skin examination, including visualization of the finger webs, anogenital region, nails, and scalp, is essential. Primary skin lesions indicate diseased skin, and secondary lesions are reactive and result from skin manipulation, such as scratching. An initial evaluation for systemic causes may include a complete blood count with differential, creatinine and blood urea nitrogen levels, liver function tests, iron studies, fasting glucose or A1C level, and a thyroid-stimulating hormone test. Additional testing, including erythrocyte sedimentation rate, HIV screening, hepatitis serologies, and chest radiography, may also be appropriate based on the history and physical examination. In the absence of primary skin lesions, physicians should consider evaluation for malignancy in older patients with chronic generalized pruritus. General management includes trigger avoidance, liberal emollient use, limiting water exposure, and administration of oral antihistamines and topical corticosteroids. If the evaluation for multiple etiologies of pruritus is ambiguous, clinicians may consider psychogenic etiologies and consultation with a specialist.


Asunto(s)
Prurito/diagnóstico , Prurito/terapia , Administración Tópica , Corticoesteroides/administración & dosificación , Anciano , Recuento de Células Sanguíneas/métodos , Sedimentación Sanguínea , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Dermatitis Atópica/complicaciones , Emolientes/administración & dosificación , Antagonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Examen Físico/métodos , Prurito/etiología , Radiografía/métodos , Derivación y Consulta , Cuero Cabelludo/patología , Piel/patología , Enfermedades de la Piel/diagnóstico , Tiña/complicaciones
11.
Med Clin North Am ; 105(4): 699-721, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-34059246

RESUMEN

Chronic pruritus (itch lasting ≥6 weeks) is a bothersome chief complaint that may present in a broad variety of diseases. Most itch-causing diagnoses fit into 1 of 5 categories (inflammatory, secondary to systemic disease, neuropathic, chronic pruritus of undetermined origin, and psychogenic itch) and this broad differential can be narrowed using key findings in the history and physical. In this article, we discuss which key findings are most pertinent for narrowing this differential and guiding further workup and treatment, as well as how to treat many itchy conditions.


Asunto(s)
Inflamación/complicaciones , Enfermedades del Sistema Nervioso Periférico/complicaciones , Prurito/diagnóstico , Prurito/etiología , Enfermedades de la Piel/patología , Administración Tópica , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Algoritmos , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/uso terapéutico , Antidepresivos/administración & dosificación , Antidepresivos/uso terapéutico , Inhibidores de la Calcineurina/administración & dosificación , Inhibidores de la Calcineurina/uso terapéutico , Enfermedad Crónica , Consejo/métodos , Detergentes/administración & dosificación , Detergentes/uso terapéutico , Diagnóstico Diferencial , Emolientes/administración & dosificación , Emolientes/uso terapéutico , Antagonistas de los Receptores Histamínicos/administración & dosificación , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Masculino , Neurotransmisores/administración & dosificación , Neurotransmisores/uso terapéutico , Apoyo Nutricional/métodos , Prurito/tratamiento farmacológico , Terapia por Relajación/métodos
12.
Biomed Res Int ; 2021: 5594646, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33954180

RESUMEN

The benefits of emollients for eczematous dermatitis and psoriasis have been thought to be due to the improvements in epidermal function, including epidermal permeability barrier, stratum corneum hydration, and stratum corneum pH. We determined here whether emollient can direct inhibit cutaneous inflammation. Ear inflammation was induced by topical application of either 12-O-tetradecanoylphorbol-13-acetate (TPA) or 1-fluoro-2,4-dinitrofluorobenzene (DNFB). Either 1% hydrocortisone cream or the novel emollient was applied to the right ear of the mice 45 min and 2 hours after TPA or DNFB application. The untreated left ear served as untreated controls. Both ear weight and ear thickness were measured 24 hours after TPA and DNFB application. Topical applications of either hydrocortisone cream or emollient significantly decreased both ear thickness and ear weight in comparison to untreated controls. In DNFB model, hydrocortisone significantly lowered expression levels of mRNA for IL-1α, IL-1ß, and TNFα, while the emollient markedly decreased expression levels of IL-1α and TNFα mRNA. In TPA model, both hydrocortisone and emollient significantly decreased expression levels of IL-1α, IL-1ß, IL-6, and TNFα mRNA. In parallel, inflammatory infiltration was also reduced by topical applications of either hydrocortisone or emollient. These results demonstrate that this novel emollient can directly inhibit cutaneous inflammation in murine models of both acute irritant contact dermatitis and acute allergic contact dermatitis. However, whether this emollient could also alleviate eczematous dermatitis in humans remains to be explored.


Asunto(s)
Antiinflamatorios , Dermatitis Alérgica por Contacto , Emolientes , Inflamación/metabolismo , Administración Tópica , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Emolientes/administración & dosificación , Emolientes/farmacología , Femenino , Ratones , Ratones Endogámicos C57BL , Piel/efectos de los fármacos , Piel/patología
13.
J Drugs Dermatol ; 20(5): 515-518, 2021 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-33938700

RESUMEN

BACKGROUND: Port-wine stain (PWS) is a congenital vascular malformation affecting 0.3–0.5% of normal population. These characteristic lesions arise due to the interplay of vascular, neural, and genetic factors. Treatment options include lasers, cosmetic tattooing, electrotherapy, cryosurgery, derma-abrasion, and skin grafting; however, none of these treatment alternatives appears to be satisfactory and is unable to provide consistent, satisfactory responses or even complete cures. Currently, laser is the treatment of choice, as it is comparatively safe and more effective than other procedures. The most commonly used modality is pulsed dye laser (PDL). The literature research includes peer-reviewed articles (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) to January 2020 and reference lists of respective articles. Only articles published in English language were included. J Drugs Dermatol. 20(5): doi:10.36849/JDD.5005.


Asunto(s)
Técnicas Cosméticas/tendencias , Dermatología/métodos , Láseres de Colorantes/uso terapéutico , Mancha Vino de Oporto/terapia , Administración Cutánea , Inhibidores de la Angiogénesis/administración & dosificación , Ensayos Clínicos como Asunto , Terapia Combinada/métodos , Técnicas Cosméticas/instrumentación , Cosméticos/administración & dosificación , Criocirugía/métodos , Criocirugía/tendencias , Dermabrasión/métodos , Dermabrasión/tendencias , Dermatología/tendencias , Terapia por Estimulación Eléctrica/métodos , Terapia por Estimulación Eléctrica/tendencias , Emolientes/administración & dosificación , Humanos , Satisfacción del Paciente , Mancha Vino de Oporto/psicología , Calidad de Vida , Piel/efectos de los fármacos , Piel/efectos de la radiación , Tatuaje/tendencias , Resultado del Tratamiento
14.
J Drugs Dermatol ; 20(4): s3-s9, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33852254

RESUMEN

Skin is a complex organ comprised of multiple cell types and microstructures that work in concert to serve critical functions and support the body’s homeostasis. It is the outermost, cornified layer of our body that is primarily responsible for the permeability barrier, protecting against external aggressors and preventing water loss from within. The understanding of the organization, functionality, and underlying mechanisms of the skin barrier has evolved greatly through the years. The formation of an intact and well-maintained stratum corneum (SC), where the permeability barrier resides, relies heavily on the differentiation of epidermal keratinocytes and the synthesis, release, localization, and binding of lipids that include principally ceramides, cholesterol, and free fatty acids. The in-depth research on SC barrier, its disruption in the pathogenesis of diseases, as well as on barrier responses to environmental insults, has enabled the development of modern therapeutics and topical care routines. Among them, ceramide-containing moisturizers have clinically demonstrated the ability to support the management of skin conditions such as atopic dermatitis and psoriasis by reducing the disease severity and recurrence and improving the patients’ perception of overall skin quality and health. This review focuses on the contributions of various barrier constituents to skin barrier function in health and pathological conditions, and how topical interventions containing essential barrier lipids support barrier restoration and provide relief. J Drugs Dermatol. 20(4 Suppl):s3-9. doi:10.36849/JDD.S589A.


Asunto(s)
Ceramidas/administración & dosificación , Dermatitis Atópica/tratamiento farmacológico , Emolientes/administración & dosificación , Epidermis/patología , Psoriasis/tratamiento farmacológico , Administración Cutánea , Diferenciación Celular/efectos de los fármacos , Ceramidas/metabolismo , Colesterol/metabolismo , Dermatitis Atópica/patología , Epidermis/efectos de los fármacos , Ácidos Grasos no Esterificados/metabolismo , Humanos , Queratinocitos/fisiología , Metabolismo de los Lípidos/efectos de los fármacos , Permeabilidad , Psoriasis/patología , Pérdida Insensible de Agua/efectos de los fármacos
15.
J Drugs Dermatol ; 20(4): s10-s16, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33852255

RESUMEN

The skin barrier is a multifaceted microenvironment, comprised not only of structural and molecular components that maintain its integrity, but also a lipid matrix comprising an equimolar ratio of cholesterol, free fatty acids, and ceramides. Lipid abnormalities induced by environmental or pathological stimuli are often associated with impaired skin barrier function and integrity. Incorporation of skin lipids in skincare formulations to help fortify barrier function has become widespread. While there are resources available to study the barrier, a comprehensive evaluation of skin models, from in situ to in vivo, that focus on alterations of the lipid content, seems to be lacking. This article reviews current methods to evaluate the skin lipid barrier and touches upon the significance of using such models within the cosmetic field to study formulations that incorporate barrier lipids. J Drugs Dermatol. 20(4 Suppl):s10-16. doi:10.36849/JDD.S589B.


Asunto(s)
Cosméticos/administración & dosificación , Emolientes/administración & dosificación , Epidermis/efectos de los fármacos , Cuidados de la Piel/métodos , Animales , Técnicas de Cultivo de Célula , Línea Celular , Ceramidas/administración & dosificación , Ceramidas/metabolismo , Colesterol/administración & dosificación , Colesterol/metabolismo , Cosméticos/química , Modelos Animales de Enfermedad , Emolientes/química , Epidermis/fisiología , Epidermis/efectos de la radiación , Ácidos Grasos no Esterificados/administración & dosificación , Ácidos Grasos no Esterificados/metabolismo , Humanos , Técnicas de Cultivo de Tejidos , Rayos Ultravioleta/efectos adversos , Pérdida Insensible de Agua/efectos de los fármacos
16.
J Drugs Dermatol ; 20(4): s29-s35, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33852258

RESUMEN

The human skin, particularly the stratum corneum, serves as a protective barrier against exogenous factors, including ultraviolet radiation (UVR) and pathogen invasions. The impact of UVR on skin cancer and photoaging has been extensively studied. However, the direct impact of UVR on skin barrier integrity under clinical settings remains poorly explored. Due to their benefits in reducing inflammation and promoting skin barrier repair, ceramide-containing formulations can provide added photoprotection benefits. In this study, the efficacy of a ceramide-containing sunscreen and moisturizer were evaluated in preventing UV-induced skin surface barrier changes. Expert grading, instrumental, and tape-stripping assessments demonstrated that UVR induced erythema and hyperpigmentation and caused changes in skin cells surface morphological organization and maturation. Treatment with a ceramide-containing sunscreen and moisturizing cream routine reduced erythema and hyperpigmentation, improved skin hydration, and maintained normal superficial skin cells morphology and turnover after UVR. Our results indicate that barrier-enforcing lipids formulations can provide additional benefits in patient’s daily routine by strengthening the barrier and improving skin health overall against chronic sun exposure. J Drugs Dermatol. 20(4 Suppl):s29-35. doi:10.36849/JDD.S589E.


Asunto(s)
Ceramidas/administración & dosificación , Eritema/prevención & control , Hiperpigmentación/prevención & control , Rayos Ultravioleta/efectos adversos , Adolescente , Adulto , Emolientes/administración & dosificación , Emolientes/química , Eritema/diagnóstico , Eritema/etiología , Eritema/patología , Femenino , Voluntarios Sanos , Humanos , Hiperpigmentación/diagnóstico , Hiperpigmentación/etiología , Hiperpigmentación/patología , Masculino , Persona de Mediana Edad , Fotograbar , Piel/diagnóstico por imagen , Piel/efectos de los fármacos , Piel/efectos de la radiación , Envejecimiento de la Piel/efectos de los fármacos , Envejecimiento de la Piel/efectos de la radiación , Protectores Solares/administración & dosificación , Protectores Solares/química , Resultado del Tratamiento , Pérdida Insensible de Agua/efectos de los fármacos , Pérdida Insensible de Agua/efectos de la radiación , Adulto Joven
17.
Sultan Qaboos Univ Med J ; 21(1): e124-e126, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33777434

RESUMEN

Verrucous epidermal nevi (VEN) are benign congenital hamartomas consisting of keratinocytes. Histological examination mostly exhibits hyperkeratosis, acanthosis, papillomatosis and, rarely, the features of epidermolytic hyperkeratosis (EHK). We report a case of a 6-year-old boy who presented at Aga Khan University Hospital, Karachi, Pakistan with bilaterally symmetrical linear epidermal nevi following Blaschko's lines and showing epidermolytic hyperkeratosis on histology. The patient was treated with topical keratolytics and emolients which led to considerable improvement. To the best of the authors' knowledge, this is the first report of VEN from Pakistan.


Asunto(s)
Emolientes/uso terapéutico , Hiperqueratosis Epidermolítica/tratamiento farmacológico , Queratolíticos/uso terapéutico , Nevo Sebáceo de Jadassohn/tratamiento farmacológico , Administración Tópica , Niño , Emolientes/administración & dosificación , Hamartoma , Humanos , Queratolíticos/administración & dosificación , Masculino , Mosaicismo , Nevo , Pakistán
18.
Int J Legal Med ; 135(4): 1267-1280, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33783604

RESUMEN

Since the first shedder test was formulated almost 20 years ago, a plethora of different test strategies has emerged. The amount of data generated so far is considerable. However, because of the limited reproducibility of its results, the reliability of the shedder concept is frequently questioned. This study provides a literature overview of applied shedder tests that capture the diversity of the concept. It is pointed out to what extent different classification criteria, workflows, and trace evaluation can impair the classification outcome. The robustness of shedder status was assessed by applying a promising approach established by Fonneløp et al. (Forensic Sci Int Genet 29:48-60, 21). Data provide similar results to those in recent studies but also ambiguous shedder classifications. The applied shedder test was adapted based on our own as well as the reviewed data. With novel classification parameters, promising results were achieved. This study reveals uncertainties and inconsistencies of the shedder concept. Recommendations for harmonization and transparency are proposed. Implementation of the recommendations may result in an increased impact on casework and transfer studies, including activity-level assessments. Furthermore, this study shows that moisturizers affect participants' shedder status as well as DNA transfer. The impact appears to remain relevant even 60 min post ointment application but depends greatly on the type of moisturizer applied.


Asunto(s)
ADN/análisis , ADN/aislamiento & purificación , Emolientes/administración & dosificación , Piel/química , Tacto , Líquidos Corporales/química , Células Epiteliales/química , Femenino , Humanos , Masculino , Reproducibilidad de los Resultados , Flujo de Trabajo
19.
J Allergy Clin Immunol ; 147(3): 967-976.e1, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33678253

RESUMEN

BACKGROUND: Food allergy is thought to develop through transcutaneous sensitization, especially in the presence of skin barrier impairment and inflammation. Regular moisturizer application to infant skin could potentially promote transcutaneous sensitization and the development of food allergy. OBJECTIVES: We tested this hypothesis in the Enquiring About Tolerance (EAT) study population. METHODS: The EAT study was a population-based randomized clinical trial conducted from January 15, 2008, to August 31, 2015, and recruited 1303 exclusively breastfed 3-month-old infants and their families from England and Wales. At enrollment at 3 months, families completed a questionnaire that included questions about frequency and type of moisturizer applied, use of corticosteroid creams, and parental report of dry skin or eczema. Infants were examined for visible eczema at the enrollment visit. RESULTS: A statistically significant dose-response relationship was observed between parent-reported moisturization frequency at 3 months of age and the subsequent development of food allergy. Each additional moisturization per week was associated with an adjusted odds ratio of 1.20 (95% CI, 1.13-1.27; P < .0005) for developing food allergy. For infants with no visible eczema at the enrollment visit, the corresponding adjusted odds ratio was 1.18 (95% CI, 1.07-1.30; P = .001) and for those with eczema at the enrollment visit, 1.20 (95% CI, 1.11-1.31; P < .0005). Moisturizer frequency showed similar dose-response relationships with the development of both food and aeroallergen sensitization at 36 months. CONCLUSIONS: These findings support the notion that regular application of moisturizers to the skin of young infants may promote the development of food allergy through transcutaneous sensitization.


Asunto(s)
Eccema/epidemiología , Emolientes/administración & dosificación , Hipersensibilidad a los Alimentos/epidemiología , Grupos de Población , Piel/inmunología , Administración Tópica , Alérgenos/inmunología , Emolientes/efectos adversos , Femenino , Proteínas Filagrina , Humanos , Inmunización , Inmunoglobulina E/metabolismo , Lactante , Masculino , Oportunidad Relativa , Reino Unido
20.
J Invest Dermatol ; 141(8): 2049-2055.e1, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33705796

RESUMEN

Computational models of skin permeability are typically based on assumptions of fixed geometry and homogeneity of the whole epidermis or of epidermal strata and are often limited to adult skin. Infant skin differs quantitatively from that of the adult in its structure and its functional properties, including its barrier function to permeation. To address this problem, we developed a self-organizing multicellular epidermis model of barrier formation with realistic cell morphology. By modulating the parameters relating to cell turnover reflecting those in adult or infant epidermis, we were able to generate accordingly two distinct models. Emerging properties of these models reflect the corresponding experimentally measured values of epidermal and stratum corneum thickness. Diffusion of an externally applied substance (e.g., caffeine) was simulated by a molecular exchange between the model agents, defined by the individual cells and their surrounding extracellular space. By adjusting the surface concentration and the intercellular exchange rate, the model can recapitulate experimental permeability data after topical exposure. By applying these parameters to an infant model, we were able to predict the caffeine concentration profile in infant skin, closely matching experimental results. This work paves the way for a better understanding of skin physiology and function during the first years of life.


Asunto(s)
Células Epidérmicas/metabolismo , Modelos Biológicos , Piel/metabolismo , Administración Cutánea , Adulto , Simulación por Computador , Dermatitis por Contacto/tratamiento farmacológico , Dermatitis por Contacto/fisiopatología , Difusión , Emolientes/administración & dosificación , Células Epidérmicas/efectos de los fármacos , Femenino , Humanos , Lactante , Masculino , Edad Materna , Permeabilidad/efectos de los fármacos , Piel/citología , Piel/efectos de los fármacos , Fenómenos Fisiológicos de la Piel/efectos de los fármacos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...